Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

Cairo University (CU)

Status and phase: Completed; Phase 2

Conditions: Neovascular Glaucoma

Treatments: Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin

Study type: Interventional

Funder types: Other

Identifiers

NCT01051583

NVG AV1

Details and patient eligibility

About

Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the treatment of Neovascular Glaucoma.

Full description

Design: Prospective, comparative interventional case series. Method: Patients were randomly assigned into Group A which were treated with Diode laser cyclophotocoagulation alone, whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow up period, and a full ophthalmological examination with emphasis on mean IOP, iris neovascularization, pain and corneal edema.

Enrollment: 16 patients

Sex: All

Ages: 14 to 72 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neovascular absolute glaucoma
• Painful blind eyes

Exclusion criteria

• Neovascular glaucoma with useful vision or potential for useful vision

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Avastin , diode laser cyclophotcoagulation

Experimental group

Description:

Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation

Treatment:

Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin

Diode Laser cyclophotocoagulation

Active Comparator group

Description:

Diode laser cyclophotocoagulation to control intraocular pressure

Treatment:

Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin